{"id":"nnc6019-0001","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL5852205","moleculeType":null,"molecularWeight":"373.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug selectively antagonizes the glucagon receptor, a G-protein coupled receptor primarily expressed on hepatocytes. By blocking glucagon's effects, it reduces hepatic glucose output, which is elevated in type 2 diabetes. This mechanism complements insulin-based therapies and may offer additional glycemic benefit with a lower hypoglycemia risk.","oneSentence":"NNC6019-0001 is a glucagon receptor antagonist that blocks glucagon signaling to reduce hepatic glucose production and improve glycemic control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:08.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07207811","phase":"PHASE3","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-10-02","conditions":"Transthyretin Amyloid Cardiomyopathy (ATTR CM)","enrollment":1280},{"nctId":"NCT05442047","phase":"PHASE2","title":"A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-02","conditions":"Transthyretin Amyloid Cardiomyopathy (ATTR CM)","enrollment":105},{"nctId":"NCT06260709","phase":"PHASE2","title":"A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-02-20","conditions":"Transthyretin Amyloid Cardiomyopathy (ATTR CM)","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NNC6019-0001","genericName":"NNC6019-0001","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NNC6019-0001 is a glucagon receptor antagonist that blocks glucagon signaling to reduce hepatic glucose production and improve glycemic control. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}